Sumanta Pal Selected Research

Gonadotropin-Releasing Hormone (GnRH)

11/2022

Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation and External Beam Radiation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sumanta Pal Research Topics

Disease

30	Neoplasms (Cancer) 12/2022 - 09/2009
19	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 10/2014
11	Prostatic Neoplasms (Prostate Cancer) 11/2022 - 02/2014
8	Carcinoma (Carcinomatosis) 12/2021 - 01/2016
4	Breast Neoplasms (Breast Cancer) 01/2017 - 09/2009
3	Neoplasm Metastasis (Metastasis) 11/2022 - 11/2011
3	Fatigue 01/2020 - 07/2016
3	Nausea 02/2019 - 07/2012
3	Disease Progression 01/2017 - 01/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 12/2017
2	Urinary Bladder Neoplasms (Bladder Cancer) 12/2021 - 01/2021
2	COVID-19 01/2021 - 01/2020
2	Hypertension (High Blood Pressure) 01/2020 - 07/2016
2	Adenocarcinoma 10/2019 - 01/2018
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 02/2013
1	Lymphadenopathy 03/2022
1	Infections 01/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Kidney Neoplasms (Kidney Cancer) 12/2021
1	Renal Insufficiency (Renal Failure) 01/2020
1	Urologic Neoplasms (Urological Cancer) 10/2019
1	Dyspnea (Shortness of Breath) 10/2018
1	Diarrhea 10/2018
1	Non-Langerhans-Cell Histiocytosis (Histiocytosis, Non Langerhans Cell) 12/2017

Drug/Important Bio-Agent (IBA)

9	cabozantinibIBA 03/2022 - 07/2016
8	Everolimus FDA Link 09/2021 - 03/2015
6	Immune Checkpoint InhibitorsIBA 03/2022 - 01/2017
6	Biomarkers (Surrogate Marker)IBA 09/2021 - 01/2017
4	atezolizumabIBA 03/2022 - 01/2020
4	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2016
4	PlatinumIBA 06/2021 - 01/2017
4	Cisplatin (Platino)FDA LinkGeneric 06/2021 - 01/2016
3	NivolumabIBA 01/2022 - 01/2017
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 02/2019
2	Hormones (Hormone)IBA 11/2022 - 03/2022
2	AndrogensIBA 11/2022 - 01/2020
2	enzalutamideIBA 03/2022 - 01/2022
2	abirateroneIBA 03/2022 - 01/2022
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 07/2016
2	IpilimumabIBA 01/2022 - 01/2020
2	COVID-19 VaccinesIBA 05/2021 - 01/2021
2	Axitinib (AG 013736)IBA 01/2021 - 03/2015
2	CytokinesIBA 01/2021 - 01/2017
2	CreatinineIBA 01/2020 - 02/2019
2	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 02/2014
2	MTOR InhibitorsIBA 06/2019 - 01/2016
2	Phosphotransferases (Kinase)IBA 06/2019 - 11/2011
2	Sunitinib (Sutent)FDA Link 02/2019 - 03/2015
2	Sorafenib (BAY 43-9006)FDA Link 02/2019 - 03/2015
2	OligonucleotidesIBA 01/2017 - 02/2013
2	Estrogen ReceptorsIBA 01/2017 - 09/2009
2	Proteins (Proteins, Gene)FDA Link 02/2014 - 02/2013
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 11/2022
1	pembrolizumabIBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	SteroidsIBA 01/2022
1	Cell-Free Nucleic AcidsIBA 12/2021
1	Circulating Tumor DNAIBA 12/2021
1	avelumabIBA 06/2021
1	Carboplatin (JM8)FDA LinkGeneric 06/2021
1	VaccinesIBA 01/2021
1	carotuximabIBA 01/2021
1	Cancer VaccinesIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	sipuleucel-T (APC8015)FDA Link 01/2021
1	EndoglinIBA 01/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021
1	FluoridesIBA 01/2020
1	cyclopropapyrroloindoleIBA 11/2019
1	Transforming Growth Factor beta (TGF-beta)IBA 11/2019
1	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 11/2019
1	Sirolimus (Rapamycin)FDA Link 06/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2019
1	pazopanib FDA Link 02/2019
1	AngiopoietinsIBA 02/2019
1	trebananibIBA 02/2019
1	Bevacizumab (Avastin)FDA Link 02/2019
1	AntigensIBA 01/2018
1	Antisense OligonucleotidesIBA 01/2018
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2018
1	Docetaxel (Taxotere)FDA Link 01/2018
1	Chimeric Antigen ReceptorsIBA 01/2018
1	apatorsenIBA 01/2018
1	alectinibIBA 12/2017
1	CrizotinibIBA 12/2017
1	Anaplastic Lymphoma KinaseIBA 12/2017
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2017
1	Immunoglobulin G (IgG)IBA 01/2017

Therapy/Procedure

26	Therapeutics 12/2022 - 09/2009
11	Drug Therapy (Chemotherapy) 01/2022 - 09/2009
5	Immunotherapy 01/2020 - 12/2015
3	Castration 03/2022 - 01/2021
3	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 01/2018
2	Radiotherapy 12/2022 - 11/2022
2	Cystectomy 12/2021 - 01/2016
2	Lymph Node Excision (Lymph Node Dissection) 09/2018 - 01/2018
2	Adjuvant Chemotherapy 07/2012 - 09/2009
1	Neoadjuvant Therapy 12/2021
1	Combination Drug Therapy (Combination Chemotherapy) 10/2019
1	Ligation 12/2017